Combined analysis of DNA methylation and gene expression profiles of osteosarcoma identified several prognosis signatures

Tian, Wen; Li, Yongsheng; Zhang, Jinghua; Li, Jijun; Gao, Jinghua

doi:10.1016/j.gene.2018.01.093

Cited by 39 publications

(34 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Their expression levels are positively associated with tumour grade and poor prognosis . By microarray dataset analysis, hypomethylation of PRAME is observed in osteosarcoma (OS), which leads to an increase in PRAME expression contributing to OS progression, indicating that PRAME could be useful for cancer diagnosis and treatment . Additionally, PRAME is homogeneously expressed in OS tissue, and knockdown of PRAME inhibits cell proliferation and colony formation and causes cell cycle arrest at G1 phase .…”

Section: Role Of Prame In Cancersmentioning

confidence: 99%

The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer

Zou

Wang

et al. 2020

Cell Proliferation

View full text Add to dashboard Cite

Preferentially expressed antigen in melanoma (PRAME), which belongs to the cancer/testis antigen (CTA) gene family, plays a pivotal role in multiple cellular processes and immunotherapy response in human cancers. PRAME is highly expressed in different types of cancers and is involved in cell proliferation, apoptosis, differentiation and metastasis as well as the outcomes of patients with cancer. In this review article, we discuss the potential roles and physiological functions of PRAME in various types of cancers. Moreover, this review highlights immunotherapeutic strategies that target PRAME in human malignancies. Therefore, the modulation of PRAME might be useful for the treatment of patients with cancer.

show abstract

Section: Role Of Prame In Cancersmentioning

confidence: 99%

The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer

Zou

Wang

et al. 2020

Cell Proliferation

View full text Add to dashboard Cite

show abstract

“…Osteosarcoma is a common malignant bone tumor, which is predominant in childhood and adolescence [1]. Multidrug chemotherapy and surgical removal of primary tumors have shown ameliorating effects [2].…”

Section: Introductionmentioning

confidence: 99%

The lncRNAs RP1-261G23.7, RP11-69E11.4 and SATB2-AS1 are a novel clinical signature for predicting recurrent osteosarcoma

et al. 2020

View full text Add to dashboard Cite

Background: Osteosarcoma is the most common primary bone malignancy in children and adolescents. In order to find factors related to its recurrence, and thus improve recovery prospects, a powerful clinical signature is needed. Long noncoding RNAs (lncRNAs) are essential in osteosarcoma processes and development, and here we report significant lncRNAs to aid in earlier diagnosis of osteosarcoma. Methods: A univariate Cox proportional hazards regression analysis and a multivariate Cox regression analysis were used to analyze osteosarcoma patients’ lncRNA expression data from the Therapeutically Applicable Research To Generate Effective Treatments (TARGET), a public database. Results: A lncRNA signature consisting of three lncRNAs (RP1-261G23.7, RP11-69E11.4 and SATB2-AS1) was selected. The signature was used to sort patients into high-risk and low-risk groups with meaningful recurrence rates (median recurrence time 16.80 vs. >128.22 months, log-rank test, P<0.001) in the training group, and predictive ability was validated in a test dataset (median 16.32 vs. >143.80 months, log-rank test, P=0.006). A multivariate Cox regression analysis showed that the significant lncRNA was an independent prognostic factor for osteosarcoma patients. Functional analysis suggests that these lncRNAs were related to the PI3K-Akt signaling pathway, the Wnt signaling pathway, and the G-protein coupled receptor signaling pathway, all of which have various, important roles in osteosarcoma development. The significant 3-lncRNA set could be a novel prediction biomarker that could aid in treatment and also predict the likelihood of recurrence of osteosarcoma in patients.

show abstract

“…Moreover, CpG islands was frequently detected in the promoter regions of the structural transcription gene [15], and abnormal CpG island hypermethylation of various tumor suppressor genes and hypomethylation of oncogenes play vital role in carcinogenesis [16,17]. At present, as a promising molecular marker of STSs, abnormal DNA methylation appears in early detection, prognosis prediction, molecular classification [18,19]. Meanwhile, multiple biological studies have also clarified that a series of methylations in gene promoter sequences is correlated with the prognosis and progression of STSs patients [20][21][22].…”

Section: Introductionmentioning

confidence: 99%

DNA methylation patterns–based subtype distinction and identification of soft tissue sarcoma prognosis

Fan

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Soft tissue sarcomas (STSs) are heterogeneous at the clinical with a variable tendency of aggressive behavior. Methods: In this study, we constructed a specific DNA methylation-based classification to identify the distinct prognosis-subtypes of STSs based on the DNA methylation spectrum from the TCGA database.Results: Eventually, samples were clustered into four subgroups, and their survival curves were distinct from each other. Meanwhile, the samples in each subgroup reflected differentially in several clinical features. Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis was also conducted on the genes of the corresponding promoter regions of the above‐described specific methylation sites, revealing that these genes were mainly concentrated in certain cancer‑associated biological functions and pathways. In addition, we calculated the differences among clustered methylation sites and performed the specific methylation sites with LASSO algorithm. The selection operator algorithm was employed to derive a risk signature model, and a prognostic signature based on these methylation sites performed well for risk stratification in STSs patients. At last, a nomogram consisted of clinical features and risk score was developed for the survival prediction. Conclusion: In conclusion, this study declares that DNA methylation-based STSs subtype classification is highly relevant for future development of personalized therapy as it identifies the prediction value of patient prognosis.

show abstract

Combined analysis of DNA methylation and gene expression profiles of osteosarcoma identified several prognosis signatures

Cited by 39 publications

References 25 publications

The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer

The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer

The lncRNAs RP1-261G23.7, RP11-69E11.4 and SATB2-AS1 are a novel clinical signature for predicting recurrent osteosarcoma

DNA methylation patterns–based subtype distinction and identification of soft tissue sarcoma prognosis

Contact Info

Product

Resources

About